Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET

Gynecological Endocrinology

Volumn 26, Issue 7, 2010, Pages 505-508

  Bahceci, Mustafa ^a   Sismanoglu, Alper ^a   Ulug, Ulun ^a  

^a German Hospital in Istanbul   (Turkey)

Author keywords

Bromocriptine; Cabergoline; Hyperprolactinaemia; Icsi et

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; GONADOTROPIN;

ADULT; AMPOULE; ARTICLE; COST OF ILLNESS; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; HYPERPROLACTINEMIA; INCIDENTAL FINDING; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; BROMOCRIPTINE; DATABASES, FACTUAL; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; INFERTILITY, FEMALE; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 77953639268     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513591003632233     Document Type: Article

References (14)

1. Molitch ME. Prolactin in human reproduction. In: Strauss III JF and Robert LB, editors. Yan and Jaffe's reproductive endocrinology; physiology pathophysiology, and clinical management. 5th ed. Philadephia, PA; 2004. p 93-123.
2. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003;2:23-32.
3. Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. Clin Endocrinol Metab 1984;59: 941-948.
4. McNeilly AS, Glasier A, Jonassen J, Howie PW. Evidence for direct inhibition of ovarian function by prolactin. J Reprod Fertil 1982;65:559-569.
5. Nawroth F. Hyperprolactinaemia and the regular menstrual cycle in asymptomatic women: should it be treated during therapy for infertility? Reprod Biomed Online 2005;11:581-588.
6. Reinthaller A, Deutinger J, Csaicsich P, Riss P, Mü ller-Tyl E, Fischl F, Janisch H. [Effect of serum prolactin on cycle stimulation and fertilization of human oocytes]. Geburtshilfe Frauenheilkd. 1987;47:246-248.
7. Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152-164.
8. Zollner U, Lanig K, Steck T, Dietl J. Assessment of endocrine status in patients undergoing in-vitro fertilization treatment. Is it necessary? Arch Gynecol Obstet 2001;265:16-20.
9. Laufer MR, Floor AE, Parsons KE, Kuntz KM, Barbieri RL, Friedman AJ. Evaluation of hormonal testing in the screening for in vitro fertilization (IVF) of women with tubal factor infertility. J Assist Reprod Genet 1995;12:93-96.
10. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228-238.
11. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255-279.
12. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518-2522.
13. Doldi N, Papaleo E, De Santis L, Ferrari A. Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs. Gynecol Endocrinol 2000;14:437-441.
14. Jinno M, Katsumata Y, Hoshiai T, Nakamura Y, Matsumoto K, Yoshimura Y. A therapeutic role of prolactin supplementation in ovarian stimulation for in vitro fertilization: the bromocriptine-rebound method. J Clin Endocrinol Metab 1997;82:3603-3611.